FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213339431> ?p ?o ?g. }

• W4213339431 endingPage "435" @default.
• W4213339431 startingPage "435" @default.
• W4213339431 abstract "435 Background: Up to 25% of all pts diagnosed with urothelial cancer present with muscle-invasive disease for whom the risk of progression or metastasis is substantial. Neoadjuvant chemotherapy prior to radical cystectomy and pelvic lymph node dissection (RC+PLND) has been shown to prolong overall survival for patients who are cisplatin (cis) eligible. The standard of care for cis-ineligible pts undergoing surgery does not include neoadjuvant therapy. Therefore, safe, and effective neoadjuvant therapies are an unmet need for cis-ineligible pts with MIBC. Enfortumab vedotin (EV) is an antibody-drug conjugate directed to Nectin-4, which is highly expressed in urothelial cancer, and has been shown to benefit locally advanced or metastatic urothelial cancer pts in Phase II and III trials, including cis-ineligible pts. Methods: Cohort H of the EV-103 phase 1b/2 trial (NCT03288545) enrolled pts with cis-ineligible cT2-T4aN0M0 MIBC who were eligible for RC+PLND and had an ECOG of 0-2. Pts received 3 cycles of neoadjuvant EV (1.25 mg/kg) on Days 1 and 8 of every 3-week cycle prior to RC+PLND. The primary endpoint of the study was pathological complete response rate (pCRR; ypT0N0) by central review. Key secondary endpoints included pathological downstaging (pDS) rate (yp T0,Tis,Ta,T1,N0) and safety. Results from a preliminary analysis are presented. Results: 22 pts were treated. Pts had cT2 (68.2%), cT3 (27.3%), and cT4 (4.5%) tumors. 68.2% pts had predominant urothelial cancer; 31.8% had a mixed histology. 19 pts completed all 3 cycles of EV. 21 underwent RC+PLND, and 1 had a partial cystectomy. 36.4% pts had a pCR. pDS was seen in 50.0% pts, with 1 case pending central pathology review. The most common EV treatment-related adverse events (TRAEs) were fatigue (45.5%), alopecia (36.4%), and dysgeusia (36.4%). 18.2% pts had Grade ≥3 EV TRAEs. No surgeries were delayed due to EV administration. 3 pts had Grade 5 AEs while on study that were unrelated to EV; in 2 pts these AEs occurred > 30 days after RC+PLND. Conclusions: Observed pCRR after neoadjuvant EV showed promising activity in cis-ineligible pts with MIBC who have a high unmet need. Adverse events were consistent with the known safety profile of EV. This first disclosure of data supports the ongoing Phase II and III programs evaluating EV in MIBC. Clinical trial information: NCT03288545." @default.
• W4213339431 created "2022-02-24" @default.
• W4213339431 creator A5015026946 @default.
• W4213339431 creator A5019289041 @default.
• W4213339431 creator A5022042647 @default.
• W4213339431 creator A5029777782 @default.
• W4213339431 creator A5050042851 @default.
• W4213339431 creator A5061181014 @default.
• W4213339431 creator A5070016877 @default.
• W4213339431 creator A5077921514 @default.
• W4213339431 creator A5087836779 @default.
• W4213339431 creator A5088312939 @default.
• W4213339431 date "2022-02-20" @default.
• W4213339431 modified "2023-10-03" @default.
• W4213339431 title "Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible." @default.
• W4213339431 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.435" @default.
• W4213339431 hasPublicationYear "2022" @default.
• W4213339431 type Work @default.
• W4213339431 citedByCount "16" @default.
• W4213339431 countsByYear W42133394312022 @default.
• W4213339431 countsByYear W42133394312023 @default.
• W4213339431 crossrefType "journal-article" @default.
• W4213339431 hasAuthorship W4213339431A5015026946 @default.
• W4213339431 hasAuthorship W4213339431A5019289041 @default.
• W4213339431 hasAuthorship W4213339431A5022042647 @default.
• W4213339431 hasAuthorship W4213339431A5029777782 @default.
• W4213339431 hasAuthorship W4213339431A5050042851 @default.
• W4213339431 hasAuthorship W4213339431A5061181014 @default.
• W4213339431 hasAuthorship W4213339431A5070016877 @default.
• W4213339431 hasAuthorship W4213339431A5077921514 @default.
• W4213339431 hasAuthorship W4213339431A5087836779 @default.
• W4213339431 hasAuthorship W4213339431A5088312939 @default.
• W4213339431 hasConcept C121608353 @default.
• W4213339431 hasConcept C126322002 @default.
• W4213339431 hasConcept C126894567 @default.
• W4213339431 hasConcept C143998085 @default.
• W4213339431 hasConcept C203092338 @default.
• W4213339431 hasConcept C2775910329 @default.
• W4213339431 hasConcept C2776694085 @default.
• W4213339431 hasConcept C2778239845 @default.
• W4213339431 hasConcept C2780352672 @default.
• W4213339431 hasConcept C535046627 @default.
• W4213339431 hasConcept C71924100 @default.
• W4213339431 hasConceptScore W4213339431C121608353 @default.
• W4213339431 hasConceptScore W4213339431C126322002 @default.
• W4213339431 hasConceptScore W4213339431C126894567 @default.
• W4213339431 hasConceptScore W4213339431C143998085 @default.
• W4213339431 hasConceptScore W4213339431C203092338 @default.
• W4213339431 hasConceptScore W4213339431C2775910329 @default.
• W4213339431 hasConceptScore W4213339431C2776694085 @default.
• W4213339431 hasConceptScore W4213339431C2778239845 @default.
• W4213339431 hasConceptScore W4213339431C2780352672 @default.
• W4213339431 hasConceptScore W4213339431C535046627 @default.
• W4213339431 hasConceptScore W4213339431C71924100 @default.
• W4213339431 hasIssue "6_suppl" @default.
• W4213339431 hasLocation W42133394311 @default.
• W4213339431 hasOpenAccess W4213339431 @default.
• W4213339431 hasPrimaryLocation W42133394311 @default.
• W4213339431 hasRelatedWork W2012557700 @default.
• W4213339431 hasRelatedWork W2022837219 @default.
• W4213339431 hasRelatedWork W2031494910 @default.
• W4213339431 hasRelatedWork W2598074874 @default.
• W4213339431 hasRelatedWork W2603025253 @default.
• W4213339431 hasRelatedWork W2907753846 @default.
• W4213339431 hasRelatedWork W2914146323 @default.
• W4213339431 hasRelatedWork W3032049527 @default.
• W4213339431 hasRelatedWork W3111145153 @default.
• W4213339431 hasRelatedWork W3129080622 @default.
• W4213339431 hasVolume "40" @default.
• W4213339431 isParatext "false" @default.
• W4213339431 isRetracted "false" @default.
• W4213339431 workType "article" @default.